期刊文献+

儿童炎症性肠病治疗现状和进展 被引量:7

Current status and progress of the pediatric inflammatory bowel disease treatment
原文传递
导出
摘要 炎症性肠病是一种多因素的肠道慢性炎症性疾病,主要分为溃疡性结肠炎、克罗恩病和未定型炎症性肠病。炎症性肠病的发病率逐年增加,并且呈现低龄化的趋势,儿童炎症性肠病越来越普遍。由于儿童正处于生长发育较快的特殊时期,导致儿童炎症性肠病与成人在临床表现、疾病类型、治疗方案、并发症等问题上有很多不同。该文对炎症性肠病尤其是儿童炎症性肠病的治疗现状和进展进行阐述。 Inflammatory bowel disease, a type of intestinal chronic inflammatory disease caused by multi-factors ,which include ulcerative colitis ,Crohn's disease and inflammatory bowel disease unclassified. The morbidity of inflammatory bowel disease has been increasing by years with a younger age trend. Nowadays the pediatric inflammatory bowel disease is prevalent. Pediatric inflammatory bowel disease is different from adult at many aspects such as clinical manifestation, disease type, treatment, complications etc. It is because children are in a special condition with fast growth and development. This article will elaborate the current stares of treatment and progresses of inflammatory bowel disease especially pediatric inflammatory bowel disease.
出处 《国际儿科学杂志》 2017年第4期241-244,共4页 International Journal of Pediatrics
关键词 炎症性肠病 儿童 营养治疗 生物制剂 Inflammatory bowel disease Children Nutritional therapy Biological agent
  • 相关文献

参考文献5

二级参考文献104

  • 1Gary E Wild,Laurie Drozdowski,Carmela Tartaglia,M Tom Clandinin,Alan BR Thomson.Nutritional modulation of the inflammatory response in inflammatory bowel disease-From the molecular to the integrative to the clinical[J].World Journal of Gastroenterology,2007,13(1):1-7. 被引量:6
  • 2[24]Rajwal SR,Puntis JW,McClean P,Davison SM,Newell SJ,Sugarman I,Stringer MD.Endoscopic rectal sparing in children with untreated ulcerative colitis.J Pediatr Gastroenterol Nutr 2004; 38:66-69
  • 3[25]Targan SR,Landers CJ,Yang H,Lodes MJ,Cong Y,Papadakis KA,Vasiliauskas E,Elson CO,Hershberg RM.Antibodies to CBirl flagellin define a unique response that is associated independently with complicated Crohn's disease.Gastroenterology 2005; 128:2020-2028
  • 4[26]Fleshner P,Vasiliauskas E,Dubinsky M,Mei L,Landers C,lppolitti A,Papadakis K,Targan S.Both Preopertaive pANCA and CBirl Flagellin Expression in Ulcerative Colitis (UC) Patients Influence Pouchitis Development after Ileal Pouch Anal Anastomosis.Gastroenterology 2006; 130:A25
  • 5[27]Borrelli O,Cordischi L,Cirulli M,Paganelli M,Labalestra V,Uccini S,Russo PM,Cucchiara S.Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease:a randomized controlled open-label trial.Clin Gastroenterol Hepatol2006; 4:744-753
  • 6[28]D'Haens GR,Hommes D,Baert F,de Vos M,Caenepeel F,van Assche G,Lambrecht G,Coche JC,Vermiere S,van Camp.A combined Regimen of Infliximab and Azathioprine induces Better endoscopic Healing than Classic Step UP Theapy in Newly Diagnosed Crohn's disease.Gateroenterology 2006; 130:A110
  • 7[29]Markowitz J,Grancher K,Kohn N,Lesser M,Daum F.A multicenter trial of 6-mercaptopurine and preclnisone in children with newly diagnosed Crohn's disease.Gastroenterology 2000; 119:895-902
  • 8[30]Dubinsky MC,Lamothe S,Yang HY,Targan SR,Sinnett D,Theoret Y,Seidman EG.Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.Gastroenterology 2000; 118:705-713
  • 9[31]Hyams J,Crandall W,Kugathasan S,Griffiths AM,Olsen A,Johanns J,Liu G,Travers S,Heuschkel R,Markowitz J,Cohen S,Winter H,Wauters G,Ferry G,Baldassano R.Maintenance Therapy with Infliximab Every 8 wk is Superior to Every 12 weeks in Maintaining Response and Remission in Pediatric Patients with Moderately to Severly Active Crohn's Disease.Gastroenterology 2006; 130:A12
  • 10[32]Hanauer SB,Feagan BG,Lichtenstein GR,Mayer LF,Schreiber S,Colombel JF,Rachmilewitz D,Wolf DC,Olson A,Bao W,Rutgeerts P.Maintenance infliximab for Crohn's disease:the ACCENT I randomised trial.Lancet 2002; 359:1541-1549

共引文献66

同被引文献48

引证文献7

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部